4.8 Article

PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells

Journal

CELL
Volume 155, Issue 2, Pages 397-409

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2013.09.025

Keywords

-

Funding

  1. NIH [R01CA168653, 5P01CA117969, P30CA147882, 5P30CA14051, 5K08CA136983, DK059635, R01DK092606, R00CA131472, R01GM056203]
  2. ADA grant [7-12-BS-09]
  3. Belfer Foundation
  4. Smith Family Foundation
  5. Burroughs Wellcome Fund
  6. Damon Runyon Cancer Research Foundation
  7. Stern family

Ask authors/readers for more resources

The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in regulating anabolic metabolism. To determine whether PKM2 is required for tumor formation or growth, we generated mice with a conditional allele that abolishes PKM2 expression without disrupting PKM1 expression. PKM2 deletion accelerated mammary tumor formation in a Brca1-loss-driven model of breast cancer. PKM2 null tumors displayed heterogeneous PKM1 expression, with PKM1 found in nonproliferating tumor cells and no detectable pyruvate kinase expression in proliferating cells. This suggests that PKM2 is not necessary for tumor cell proliferation and implies that the inactive state of PKM2 is associated with the proliferating cell population within tumors, whereas nonproliferating tumor cells require active pyruvate kinase. Consistent with these findings, variable PKM2 expression and heterozygous PKM2 mutations are found in human tumors. These data suggest that regulation of PKM2 activity supports the different metabolic requirements of proliferating and nonproliferating tumor cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available